Statistical Analysis of Cost-effectiveness Data
For Bernie

All author proceeds donated
to the Emma and Lucy O'Brien Education Fund.
Contents

Preface xi

1 Concepts 1
   1.1 Introduction 1
   1.2 Cost-effectiveness data and the parameters of interest 2
   1.3 The cost-effectiveness plane, the ICER and INB 5
   1.4 Outline 8

2 Parameter Estimation for Non-censored Data 11
   2.1 Introduction 11
   2.2 Cost 12
      2.2.1 Sample means for estimating incremental cost 12
      2.2.2 Using multiple regression models 14
      2.2.3 Transformation (and the retransformation problem) 15
      2.2.4 Generalized linear models 17
      2.2.5 Two-part models for excess zeros 18
      2.2.6 Cost prediction models 19
   2.3 Effectiveness 20
      2.3.1 Probability of surviving 21
      2.3.2 Mean survival time 21
      2.3.3 Mean quality-adjusted survival time 22
      2.3.4 Mean quality-adjusted survival: controlling for baseline utility 24
   2.4 Summary 25

3 Parameter Estimation for Censored Data 27
   3.1 Introduction 27
   3.2 Mean Cost 28
      3.2.1 Direct (Lin) method 29
      3.2.2 Inverse-probability weighting 31
   3.3 Effectiveness 34
      3.3.1 Probability of surviving 34
Contents

3.3.2 Mean survival time 36
3.3.3 Mean quality-adjusted survival time 39
3.4 Summary 42

4 Cost-effectiveness Analysis 43
4.1 Introduction 43
4.2 Incremental cost-effectiveness ratio 44
4.3 Incremental net benefit 49
4.4 The cost-effectiveness acceptability curve 51
4.5 Using bootstrap methods 54
4.6 A Bayesian incremental net benefit approach 57
4.7 Kinked thresholds 60
4.8 Summary 64

5 Cost-effectiveness Analysis: Examples 67
5.1 Introduction 67
5.2 The CADET-Hp trial 67
5.3 Symptomatic hormone-resistant prostate cancer 72
5.4 The Canadian implantable defibrillator study (CIDS) 77
5.5 The EVALUATE trial 82
5.6 Bayesian approach applied to the UK PDS study 86
5.7 Summary 90

6 Power and Sample Size Determination 93
6.1 Introduction 93
6.2 Approaches based on the cost-effectiveness plane 94
   6.2.1 Briggs and Gray 95
   6.2.2 Willan and O’Brien 98
   6.2.3 Gardiner et al. 101
6.3 The classical approach based on net benefit 103
   6.3.1 The method 103
   6.3.2 Example 105
6.4 Bayesian take on the classical approach 106
   6.4.1 The Method 106
   6.4.2 Example 107
6.5 The value of information approach 108
   6.5.1 The method 108
   6.5.2 Example 114
6.6 Summary 116

7 Covariate Adjustment and Sub-group Analysis 117
7.1 Introduction 117
7.2 Non-censored data 118
   7.2.1 Example, non-censored data 121
7.3 Censored data
  7.3.1 Cost
  7.3.2 Quality-adjusted survival time
  7.3.3 Survival time
  7.3.4 The Canadian implantable defibrillator study (CIDS)
  7.3.5 The evaluate trial
7.4 Summary

8 Multicenter and Multinational Trials
  8.1 Introduction
  8.2 Background to multinational cost-effectiveness
  8.3 Fixed effect approaches
    8.3.1 Willke et al.
    8.3.2 Cook et al.
  8.4 Random effects approaches
    8.4.1 Aggregate level analysis: multicenter trials
    8.4.2 Aggregate level analysis: multinational trials
    8.4.3 Hierarchical modeling
  8.5 Summary

9 Modeling Cost-effectiveness
  9.1 Introduction
  9.2 A general framework for modeling cost-effectiveness results
  9.3 Case study: an economic appraisal of the goal study
    9.3.1 The GOAL study
    9.3.2 Standard approach to estimating cost-effectiveness
    9.3.3 An alternative approach to estimating cost-effectiveness
    9.3.4 Comparing the two analyses of GOAL
  9.4 Summary

References

Author Index

Subject Index

Series List
Preface

This book describes statistical methods applied to cost-effectiveness analysis. It represents the experience over many years of the author's involvement in the application and methodology of health economic evaluation. The focus on randomised clinical trials reflects the fact that the trend towards collecting not only clinical, but also economic, data alongside clinical trials was the driving force behind many of the methodological developments described in the text. Health economics is a relatively young discipline and the use of clinical trials as a vehicle for economic evaluations began in earnest only twenty years ago.

As a consequence, there has been a high degree of methodological development since then, with most of the reporting confined to journal articles. The aim of this book is to draw together those developments in a single source which we hope will be of interest to students of statistics, keen to understand more about health economics, and students of health economics, keen to understand the statistical methods required for undertaking economic evaluation of health care interventions. The exposition is at a technical level roughly equivalent to that found in final year undergraduate mathematics and statistics courses or postgraduate social sciences courses.

The book itself naturally divides into two parts. The first part (up to Chapter 5) deals with the established approach for the presentation of cost-effectiveness analyses, with a focus on estimating health outcomes and resource use costs. The second part of the book (Chapters 6 through 9) handles specific issues in more depth to give a fuller understanding of the nuances of a modern cost-effectiveness analysis where patient-level data are available.
In the preparation of any book there are numerous colleagues and students who have provided the inspiration and insight, as well as friends and family who have provided the encouragement and support, necessary to bring such a project to fruition. We are extremely grateful to all those people who have helped us over the years and aided us to a greater or lesser extent in supporting our endeavours and correcting our mistakes. However, one person stands out as the true inspiration for this book. A friend and colleague who had a major influence on both of our careers in the area of health economic evaluation, albeit in different ways, Bernie O’Brien was a rare person – someone with a keen intellect, an infectious enthusiasm, and a generosity of ideas that could not fail to rub off on those around him. His untimely death on the 13th of February, 2004 was a terrible shock and leaves a vacuum in the health economics community, as well as for his wife Karen and daughters, Emma and Lucy. We dedicate this book to Bernie’s memory.